secwatch.observer — SEC 8-K summary
======================================

Issuer:     RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK:        0001649904
Form:       8-K
Filed at:   2024-11-05T23:59:59+00:00
Accession:  0001104659-24-114304
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rhythm Pharma Q3 revenue $33.3M (+14% seq); FDA Priority Review for label expansion to age 2
--------------------------------------------------------------------------------

- IMCIVREE net revenue $33.3M (Q3 2024), up 48% YoY from $22.5M; US sales $23.3M (+8% seq), ex-US $10.0M (+35% seq).
- Net loss $(45.0)M ($(0.73)/share) vs $(44.2)M ($(0.76)/share) in Q3 2023; cash $298.4M at Sep 30, 2024.
- FDA accepted sNDA for Priority Review to treat children as young as 2 years; PDUFA date Dec 26, 2024.
- Phase 3 hypothalamic obesity trial top-line data on track for 1H 2025; early-access French data showed 12.8% BMI reduction at 3 months.
- FY 2024 non-GAAP operating expense guidance narrowed to $245-255M from $250-270M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649904/000110465924114304/0001104659-24-114304-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649904/000110465924114304/tm2427018d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-114304

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer